Market Overview:
The global bone cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of bone cancer, rising awareness about bone cancer and its treatment options, and technological advancements in the field of bone cancer drugs. The global Bone Cancer Drugs Market by type is segmented into chemotherapy and targeted therapy. The chemotherapy segment is further sub-segmented into traditional chemotherapeutic agents and novel chemotherapeutic agents. The targeted therapy segment is further sub-segmented into monoclonal antibodies (mAbs), small molecule inhibitors, tyrosine kinase inhibitors (TKIs), and other targeted therapies. Of these, the chemotherapy segment dominates the global Bone Cancer Drugs Market by type due to high adoption rates for traditional chemotherapeutic agents as well as novel chemotherapeutic agents across regions owing to their high efficacy in treating various types of cancers including bone cancers. However, with increasing focus on precision medicine for better patient outcomes, the targeted therapy segment is expected to witness higher growth rates during the forecast period from 2018 to 2030.
Product Definition:
Bone cancer drugs are used to treat bone tumors. They work by stopping the tumor from growing and spreading.
Chemotherapy:
Chemotherapy is the use of drugs or other substances to treat cancer. The most common types of cancers that require chemotherapy are breast cancer, lung cancer, prostate cancer and bone tumors. Chemotherapy can be used with radiation therapy or surgery (in case of local control).
Factors such as growing geriatric population base coupled with increasing disposable income in emerging economies like India and China are expected to drive the global market during the forecast period.
Targeted Therapy:
Targeted therapy is a type of chemotherapy that delivers only specific drugs to cancer cells. It reduces the level of unneeded proteins, called proteases, in the blood and bone marrow. The reduced levels of these proteins decrease the ability of cancer cells to grow and develop into tumors.
Application Insights:
The primary bone cancer segment held the largest share of revenue in 2017. This is due to the increasing incidence of osteosarcoma and Ewing¢â‚¬â„¢s tumor which are mainly seen in children and young adults, respectively. The chemotherapy based drugs are generally used for treating primary bone cancers as they have a higher success rate than targeted therapy or surgery. However, new research is being carried out regarding the use of targeted therapy drugs for treating primary bone cancers as well as metastatic bones tumors that have not responded to other treatments such as chemotherapy or radiation therapy.
The secondary bone cancer application segment is expected to witness lucrative growth over the forecast period owing to an increase in awareness about early diagnosis and treatment among patients suffering from metastatic tumors at various sites within their bodies including lungs, liver & kidneys etc.
Regional Analysis:
North America dominated the global bone cancer drugs market in 2017. Key factors contributing to its growth include favorable government initiatives, high healthcare expenditure, and availability of effective treatment methods. For instance, the National Cancer Institute (NCI) is a part of NIH that conducts research on cancer and helps translate this research into clinical practice by providing information to the public as well as health professionals about all types of cancers; their causes; symptoms; diagnosis; and treatments. NCI also provides funding for ongoing clinical trials through its Center Grant Programmes (CGP).
In addition to this, increasing number of FDA-approved drug products in U.S., rising awareness among people & population increase are some other factors expected to drive revenue growth over the forecast period.
Growth Factors:
- Increasing incidence of bone cancer
- Growing awareness about bone cancer drugs and their benefits
- Rising demand for better and more effective treatments for bone cancer
- Technological advancements in the field of bone cancer drugs development 5. Availability of government funding for research on new bone cancer drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Bone Cancer Drugs Market Research Report
By Type
Chemotherapy, Targeted Therapy
By Application
Primary Bone Cancer, Secondary Bone Cancer
By Companies
Pfizer, Bayer, Novartis, Amgen, Merck, Takeda Pharmaceutical, Johnson＆Johnson, Bristol-Myers Squibb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
192
Number of Tables & Figures
135
Customization Available
Yes, the report can be customized as per your need.
Global Bone Cancer Drugs Market Report Segments:
The global Bone Cancer Drugs market is segmented on the basis of:
Types
Chemotherapy, Targeted Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Primary Bone Cancer, Secondary Bone Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Bayer
- Novartis
- Amgen
- Merck
- Takeda Pharmaceutical
- Johnson＆Johnson
- Bristol-Myers Squibb
Highlights of The Bone Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Targeted Therapy
- By Application:
- Primary Bone Cancer
- Secondary Bone Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bone Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bone cancer drugs are medications that are used to treat bone cancer. Bone cancer can occur in any part of the body, but is most commonly found in the bones. Bone cancer can be treated with a variety of different medications, including chemotherapy and radiation therapy.
Some of the major players in the bone cancer drugs market are Pfizer, Bayer, Novartis, Amgen, Merck, Takeda Pharmaceutical, Johnson＆Johnson, Bristol-Myers Squibb.
The bone cancer drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bone Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bone Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bone Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bone Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bone Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Bone Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Bone Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Bone Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Bone Cancer Drugs Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Targeted Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Bone Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Bone Cancer Drugs Market Size Forecast by Applications
6.2.1 Primary Bone Cancer
6.2.2 Secondary Bone Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bone Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bone Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Bone Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Bone Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Bone Cancer Drugs Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Targeted Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Bone Cancer Drugs Market Size Forecast by Applications
9.10.1 Primary Bone Cancer
9.10.2 Secondary Bone Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Bone Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Bone Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Bone Cancer Drugs Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Targeted Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Bone Cancer Drugs Market Size Forecast by Applications
10.10.1 Primary Bone Cancer
10.10.2 Secondary Bone Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Bone Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Bone Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Bone Cancer Drugs Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Targeted Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Bone Cancer Drugs Market Size Forecast by Applications
11.10.1 Primary Bone Cancer
11.10.2 Secondary Bone Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Bone Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Bone Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Bone Cancer Drugs Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Targeted Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Bone Cancer Drugs Market Size Forecast by Applications
12.10.1 Primary Bone Cancer
12.10.2 Secondary Bone Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Bone Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Bone Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Bone Cancer Drugs Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Targeted Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Bone Cancer Drugs Market Size Forecast by Applications
13.10.1 Primary Bone Cancer
13.10.2 Secondary Bone Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bone Cancer Drugs Market: Competitive Dashboard
14.2 Global Bone Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Bayer
14.3.3 Novartis
14.3.4 Amgen
14.3.5 Merck
14.3.6 Takeda Pharmaceutical
14.3.7 Johnson＆Johnson
14.3.8 Bristol-Myers Squibb
